1. Home
  2. HYMC vs CASI Comparison

HYMC vs CASI Comparison

Compare HYMC & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HYMC
  • CASI
  • Stock Information
  • Founded
  • HYMC N/A
  • CASI 1991
  • Country
  • HYMC United States
  • CASI China
  • Employees
  • HYMC N/A
  • CASI N/A
  • Industry
  • HYMC Precious Metals
  • CASI Biotechnology: Pharmaceutical Preparations
  • Sector
  • HYMC Basic Materials
  • CASI Health Care
  • Exchange
  • HYMC Nasdaq
  • CASI Nasdaq
  • Market Cap
  • HYMC 50.2M
  • CASI 58.8M
  • IPO Year
  • HYMC N/A
  • CASI 1996
  • Fundamental
  • Price
  • HYMC $2.16
  • CASI $3.07
  • Analyst Decision
  • HYMC
  • CASI Strong Buy
  • Analyst Count
  • HYMC 0
  • CASI 1
  • Target Price
  • HYMC N/A
  • CASI $6.00
  • AVG Volume (30 Days)
  • HYMC 159.8K
  • CASI 56.2K
  • Earning Date
  • HYMC 11-05-2024
  • CASI 11-15-2024
  • Dividend Yield
  • HYMC N/A
  • CASI N/A
  • EPS Growth
  • HYMC N/A
  • CASI N/A
  • EPS
  • HYMC N/A
  • CASI N/A
  • Revenue
  • HYMC N/A
  • CASI $22,055,000.00
  • Revenue This Year
  • HYMC N/A
  • CASI N/A
  • Revenue Next Year
  • HYMC N/A
  • CASI $134.79
  • P/E Ratio
  • HYMC N/A
  • CASI N/A
  • Revenue Growth
  • HYMC N/A
  • CASI N/A
  • 52 Week Low
  • HYMC $1.87
  • CASI $2.05
  • 52 Week High
  • HYMC $4.65
  • CASI $8.19
  • Technical
  • Relative Strength Index (RSI)
  • HYMC 45.70
  • CASI 39.36
  • Support Level
  • HYMC $1.99
  • CASI $2.50
  • Resistance Level
  • HYMC $2.43
  • CASI $3.47
  • Average True Range (ATR)
  • HYMC 0.13
  • CASI 0.47
  • MACD
  • HYMC -0.01
  • CASI 0.05
  • Stochastic Oscillator
  • HYMC 37.78
  • CASI 38.78

About HYMC Hycroft Mining Holding Corporation

Hycroft Mining Holding Corp is a gold and silver producer. Its operating mine, the Hycroft Mine, is an open-pit heap leach operation located approximately fifty four miles west of Winnemucca, Nevada.

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Share on Social Networks: